BWX Technologies, Inc. (BWXT): Results of Operations and Financial Condition
BWX Technologies, Inc. (BWXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. BWX Technologies Reports Second Quarter 2026 Results • 2Q26 revenues of $901.6 million • 2Q26 net income of $89.1 million, adjusted EBITDA (1) of $155.5 million • 2Q26 diluted GAAP EPS of $0.97, non-GAAP (1) EPS of $1.07 • Announced the sale of the medical business, enabling incr
How this was made
The 30-second read
Why it matters
The company raised full-year 2026 guidance across adjusted EBITDA, non-GAAP EPS, and free cash flow, citing strong execution, Commercial Operations growth, and PCG contribution, while shifting focus away from medical.
Market read
This is a primary earnings and guidance update with explicit upward ranges, making it a direct input to near-term valuation and positioning.
What to watch
Free cash flow guidance and working-capital timing can swing quarter to quarter; traders should watch whether 2H26 execution matches the raised ranges.
BWX Technologies Reports Second Quarter 2026 Results
Revenue, GAAP EPS, net income and adjusted EBITDA increased year over year, led by 72% Commercial Operations revenue growth, while the company raised 2026 revenue, adjusted EBITDA, non-GAAP EPS and free cash flow guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Consolidated revenuesGAAP | $901.6 million | – | 18% |
| Consolidated operating incomeGAAP | $114.1 million | – | 11% |
| Consolidated operating incomenon-GAAP | $126.6 million | – | 5% |
| Government Operations operating incomeGAAP | $105.7 million | – | (3)% |
| Commercial Operations operating incomeGAAP | $24.3 million | – | 254% |
| Unallocated Corporate expenseGAAP | $(15.9) million | – | 14% |
| Diluted EPSGAAP | $0.97 | – | 14% |
| Diluted EPSnon-GAAP | $1.07 | – | 5% |
| Net incomeGAAP | $89.1 million | – | 14% |
| Net incomenon-GAAP | $98.6 million | – | 6% |
| Government Operations adjusted EBITDAnon-GAAP | $126.5 million | – | (5)% |
| Commercial Operations adjusted EBITDAnon-GAAP | $36.1 million | – | 123% |
| Unallocated Corporate adjusted EBITDAnon-GAAP | $(7.1) million | – | 116% |
| Consolidated adjusted EBITDAnon-GAAP | $155.5 million | – | 7% |
| Operating cash flowGAAP | $156.4 million | – | (2)% |
| Capital expendituresother | $41.4 million | – | 27% |
| Free cash flownon-GAAP | $115.0 million | – | (9)% |
| Dividends paidother | $24.7 million | – | 6% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Government OperationsGrowth in naval propulsion and special materials, partially offset by lower advanced nuclear volumes. | $601.3 million | – | 2% |
| Commercial OperationsGrowth in commercial nuclear components, field services, fuel handling, medical, and contribution from Kinectrics, partially offset by slightly lower fuel revenue. | $302.5 million | – | 72% |
Year Ending December 31, 2026 outlook
- Revenue~$3,800 million
- NoteAdjusted EBITDA (non-GAAP): $662 million - $672 million
- NoteNon-GAAP Earnings Per Share: $4.70 - $4.80
- NoteFree Cash Flow (non-GAAP): $345 million - $360 million
Capital returns
- BWXT paid $24.7 million, or $0.27 per common share, to shareholders in the second quarter of 2026.
- On July 31, 2026, the Board of Directors declared a quarterly cash dividend of $0.27 per common share payable on September 4, 2026, to shareholders of record on August 18, 2026.
What drove it
- Government Operations revenue growth was driven by naval propulsion and special materials.
- Commercial Operations revenue growth included commercial nuclear components, field services, fuel handling, medical and Kinectrics.
- Commercial Operations operating-income growth reflected higher revenue and solid operational performance, partly offset by SG&A investment to support growth.
- The company closed the acquisition of Precision Components Group, LLC on July 1, 2026, and 2026 guidance includes its contribution.
- The announced sale of the medical business is intended to increase focus and resources on nuclear national security and commercial nuclear power markets.
Concerns
- Government Operations operating income declined due to higher positive contract adjustments in the same quarter last year and less favorable mix, partly offset by higher technical services equity income.
- Government Operations adjusted EBITDA declined 5%.
- Unallocated Corporate expense increased 14%, and Unallocated Corporate adjusted EBITDA was $(7.1) million compared with $(3.3) million.
- Free cash flow declined 9% and capital expenditures increased 27%, primarily due to timing of growth projects in Commercial Operations.
- Lower advanced nuclear volumes and slightly lower fuel revenue partially offset segment revenue growth.
What to watch
- Execution against 2026 revenue guidance of ~$3,800 million.
- Contribution from Precision Components Group, LLC following its July 1, 2026 acquisition.
- Commercial Operations growth and the level of SG&A investment required to support it.
- Government Operations mix, advanced nuclear volumes and contract adjustments.
- Free cash flow delivery against $345 million - $360 million of 2026 guidance.
- Progress on the announced sale of the medical business and the company's increased focus on its core nuclear markets.
Balance sheet and cash flow
- Operating cash flow was $156.4 million, compared with $159.0 million.
- Capital expenditures were $41.4 million, compared with $32.7 million.
- Free cash flow was $115.0 million, compared with $126.3 million.
- Operating cash flow was modestly lower as higher net income, an increase in advanced billings, and good working capital management were offset by timing of income tax payments.
Analysis
BWXT reported a strong second quarter, with consolidated revenue of $901.6 million, up 18%, and GAAP operating income of $114.1 million, up 11%. GAAP net income rose 14% to $89.1 million and diluted GAAP EPS rose 14% to $0.97. Non-GAAP operating income increased 5% to $126.6 million, non-GAAP net income increased 6% to $98.6 million, and non-GAAP EPS increased 5% to $1.07.
Commercial Operations was the primary growth contributor. Segment revenue increased 72% to $302.5 million, driven by commercial nuclear components, field services, fuel handling, medical, Kinectrics and other activity. Commercial operating income increased 254% to $24.3 million and adjusted EBITDA increased 123% to $36.1 million. Management cited higher revenue and solid operational performance, offset in part by SG&A investment to support growth.
Government Operations revenue increased 2% to $601.3 million, supported by naval propulsion and special materials, while lower advanced nuclear volumes were a partial offset. Government operating income declined 3% to $105.7 million and adjusted EBITDA declined 5% to $126.5 million. The company attributed the profit decline to higher positive contract adjustments in the prior-year quarter and less favorable mix, partly offset by higher technical services equity income. Higher corporate expense was also a partial offset to consolidated earnings growth.
Cash conversion was lower in the quarter. Operating cash flow was $156.4 million, down 2%, and free cash flow was $115.0 million, down 9%, while capital expenditures increased 27% to $41.4 million. Management cited income-tax-payment timing as the offset to higher net income, increased advanced billings and working capital management. BWXT paid $24.7 million of dividends and declared a $0.27 per common share quarterly cash dividend.
The company raised its 2026 guidance, including revenue of ~$3,800 million, adjusted EBITDA of $662 million - $672 million, non-GAAP EPS of $4.70 - $4.80 and free cash flow of $345 million - $360 million. Guidance includes the contribution from PCG, acquired on July 1, 2026. The announced sale of the medical business accompanies a strategy to focus resources on nuclear national security and commercial nuclear power markets.
Management, verbatim
We had strong second quarter 2026 results that were ahead of our expectations.
Rex. D. Geveden, president and chief executive officer
Demand for new nuclear solutions is remarkably deep and broad, complementing our strong and growing base of highly predictable revenue streams in our Government and Commercial segments.
Rex. D. Geveden, president and chief executive officer
We now anticipate adjusted EBITDA of $662 million-$672 million, non-GAAP EPS of $4.70-$4.80, and $345 million-$360 million of free cash flow.
Rex. D. Geveden, president and chief executive officer
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating expenses guidance
- Tax rate and tax-rate guidance
- Cash balance
- Debt balance
- Share repurchases
- Prior-quarter comparisons for reported metrics
- GAAP full-year 2026 guidance
- Previous-release outlook section for formal actual-versus-prior-guidance comparisons
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BWX Technologies filed an 8-K for 2Q26 results, including a sale of its medical business and the recently closed Precision Components Group (PCG) acquisition.
Ticker impact
BWX Technologies reported 2Q26 results and raised 2026 adjusted EBITDA to $662M-$672M, non-GAAP EPS to $4.70-$4.80, and FCF to $345M-$360M.
Likely near-term positive bias as traders reprice 2026 EBITDA, EPS, and free cash flow expectations.
The filing is a primary disclosure (8-K with earnings release) and includes explicit upward guidance ranges and quarterly financial results, which typically drive repricing versus prior guidance.
Market effects
Reinforces demand visibility in nuclear national security and commercial nuclear power supply chains, potentially supporting sentiment for defense-nuclear and nuclear components peers.
Limited direct regional impact; company-specific nuclear supply chain narrative may influence broader US defense-industrial sentiment.
Moderate, as nuclear power and defense supply chains are globally relevant but the disclosure is primarily US-focused.
Counterpoint
Commercial Operations growth may be partly acquisition- and mix-driven, so organic demand durability could be less strong than headline guidance implies.
Key entities
- public_companyBWX Technologies, Inc.
Reported 2Q26 financial results and raised 2026 guidance; announced sale of medical business and PCG acquisition contribution.
- acquired_businessPrecision Components Group, LLC (PCG)
Acquisition closed July 1, 2026, establishing a US footprint for commercial nuclear component manufacturing and included in 2026 guidance.
- divested_businessMedical business
Announced sale enables increased focus on core nuclear national defense and commercial nuclear power markets.
